Clinical trials: Advanced Solid Tumors With KRAS G12C Mutations
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).
To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid tumors.
- Trial name
- NCT04380753
- Testing
- AMG 510
- Where
- 4 sites in Hong Kong, Taiwan
- Volunteers
- 12 people
- Sponsor
- Amgen
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
The reason for this study is to see if the study drug LY3499446 is safe and effective in participants with solid tumors with KRAS G12C mutation.
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT04165031
- Testing
- LY3499446, Abemaciclib, Cetuximab
- Where
- 6 sites in United States, Australia
- Volunteers
- 5 people
- Sponsor
- Eli Lilly and Company